SCHEMBL5542191

SCHEMBL5542191

Cc1ccnc2c([O])cccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 4/20 0.61
COPS5 Q92905 2/20 0.61
CCR1 P32246 3/20 0.59
CCR8 P51685 3/20 0.59
CCR5 P51681 2/20 0.59
L3MBTL1 Q9Y468 4/20 0.50
HTT P42858 2/20 0.47
SLC6A2 P23975 1/20 0.47
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTR1A P08908 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
NPC1 O15118 1/20 0.42
HSP90AA1 P07900 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2A6 P11509 1/20 0.41
SLC40A1 Q9NP59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545027 0.84 HTT (0.61) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL2607397 0.81 PSMD14 (0.68) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL13484093 0.78 CCR1 (0.68) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL12533426 0.77 PSMD14 (0.62) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL3272867 0.77 PSMD14 (0.58) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL516343 0.76 PSMD14 (0.61) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL3271557 0.76 PSMD14 (0.61) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL1187430 0.76 HTT (0.72) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL21033695 0.76 PSMD14 (0.61) PSMD14COPS5CCR1CCR8CCR5
SCHEMBL5540642 0.76 HTR1A (0.56) PSMD14COPS5CCR1CCR8CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PSMD14 3910/4885COPS5 3692/4885CCR1 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.